CO5560582A2 - Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo - Google Patents

Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo

Info

Publication number
CO5560582A2
CO5560582A2 CO04017609A CO04017609A CO5560582A2 CO 5560582 A2 CO5560582 A2 CO 5560582A2 CO 04017609 A CO04017609 A CO 04017609A CO 04017609 A CO04017609 A CO 04017609A CO 5560582 A2 CO5560582 A2 CO 5560582A2
Authority
CO
Colombia
Prior art keywords
antibody
cdr
fragment
human
extracellular region
Prior art date
Application number
CO04017609A
Other languages
English (en)
Spanish (es)
Inventor
Shitara Kenya
Nakamura Kazuyasu
Emi Hosaka
Akiko Tanaka
Koike Masamichi
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of CO5560582A2 publication Critical patent/CO5560582A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
CO04017609A 2001-08-31 2004-02-27 Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo CO5560582A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31

Publications (1)

Publication Number Publication Date
CO5560582A2 true CO5560582A2 (es) 2005-09-30

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04017609A CO5560582A2 (es) 2001-08-31 2004-02-27 Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo

Country Status (22)

Country Link
US (8) US7504104B2 (enExample)
EP (1) EP1449850B9 (enExample)
JP (1) JP4052515B2 (enExample)
KR (1) KR100959248B1 (enExample)
CN (1) CN100430420C (enExample)
AT (1) ATE490277T1 (enExample)
AU (1) AU2002338015B8 (enExample)
BE (1) BE2019C006I2 (enExample)
BR (1) BRPI0212266B8 (enExample)
CA (1) CA2458627C (enExample)
CO (1) CO5560582A2 (enExample)
CY (2) CY1111193T1 (enExample)
DE (1) DE60238503D1 (enExample)
DK (1) DK1449850T3 (enExample)
ES (1) ES2356190T3 (enExample)
FR (1) FR19C1028I2 (enExample)
LU (1) LUC00116I2 (enExample)
MX (1) MXPA04001894A (enExample)
NL (1) NL300985I2 (enExample)
NO (1) NO334858B1 (enExample)
PT (1) PT1449850E (enExample)
WO (1) WO2003018635A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278003B2 (en) * 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP3926153B2 (ja) 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1491209A4 (en) * 2002-02-28 2006-05-17 Kyowa Hakko Kogyo Kk MEANS FOR DIAGNOSIS AND TREATMENT OF INTERSTITIAL PNEUMONIA
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
WO2005035582A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
DE602004029934D1 (de) * 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
EP1871807B1 (en) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
JP5709061B2 (ja) * 2009-09-10 2015-04-30 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
AU2011289426A1 (en) 2010-08-10 2013-02-28 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
TWI666447B (zh) 2010-12-16 2019-07-21 建南德克公司 關於ｔｈ２抑制作用之診斷及治療
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連脊髄症患者の治療方法および治療剤
JP6751344B2 (ja) 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
CN106413751A (zh) 2014-05-21 2017-02-15 辉瑞大药厂 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
CA2992238A1 (en) 2015-07-14 2017-01-19 Kyowa Hakko Kirin Co., Ltd. A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
KR20200098590A (ko) * 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
IL320293A (en) 2022-10-18 2025-06-01 Meiji Seika Pharma Co Ltd Therapeutic agent for T cell malignancies
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞
WO2025212536A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Therapeutic antibody epitope-tagged car t cells for enhanced control and safety

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
TR200001228T2 (tr) 1997-11-12 2001-01-22 F.Hoffmann-La Roche Ag T yardımcı hücre tür 2 kökenli bağışıklık hastalıklarının retinoit antagonistlerle tedavisi
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
HUP0102380A3 (en) 1998-06-26 2004-06-28 Chugai Pharmaceutical Co Ltd Remedies for hypercalcemic crisis
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
JP3926153B2 (ja) * 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
DE602004029934D1 (de) * 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament

Also Published As

Publication number Publication date
CN1575303A (zh) 2005-02-02
JPWO2003018635A1 (ja) 2004-12-09
ES2356190T3 (es) 2011-04-05
US20130273038A1 (en) 2013-10-17
US7842797B2 (en) 2010-11-30
JP4052515B2 (ja) 2008-02-27
FR19C1028I1 (enExample) 2019-05-17
EP1449850A4 (en) 2005-08-10
CA2458627A1 (en) 2003-03-06
CY1111193T1 (el) 2015-06-11
KR20040044492A (ko) 2004-05-28
CY2019022I2 (el) 2019-11-27
LUC00116I1 (enExample) 2019-05-02
CN100430420C (zh) 2008-11-05
US20030175273A1 (en) 2003-09-18
EP1449850B1 (en) 2010-12-01
US20140186349A1 (en) 2014-07-03
US20110059524A1 (en) 2011-03-10
BRPI0212266B1 (pt) 2020-05-05
BE2019C006I2 (enExample) 2021-11-22
US8900584B2 (en) 2014-12-02
LUC00116I2 (enExample) 2019-12-27
ATE490277T1 (de) 2010-12-15
EP1449850A1 (en) 2004-08-25
US8143058B2 (en) 2012-03-27
NL300985I2 (en) 2019-11-21
DK1449850T3 (da) 2011-02-14
KR100959248B1 (ko) 2010-05-26
US7504104B2 (en) 2009-03-17
US9051371B2 (en) 2015-06-09
CA2458627C (en) 2013-09-10
FR19C1028I2 (fr) 2021-02-19
PT1449850E (pt) 2011-02-02
AU2002338015B8 (en) 2008-03-20
DE60238503D1 (de) 2011-01-13
AU2002338015B2 (en) 2008-02-07
MXPA04001894A (es) 2005-09-08
US10590203B2 (en) 2020-03-17
NO334858B1 (no) 2014-06-23
US20120177643A1 (en) 2012-07-12
EP1449850B9 (en) 2011-05-11
HK1073851A1 (zh) 2005-10-21
WO2003018635A1 (fr) 2003-03-06
US20150315285A1 (en) 2015-11-05
NL300985I1 (en) 2019-05-08
US10131711B2 (en) 2018-11-20
CY2019022I1 (el) 2019-11-27
BR0212266A (pt) 2004-10-19
NO20040976L (no) 2004-06-01
BRPI0212266B8 (pt) 2021-05-25
US20180030146A1 (en) 2018-02-01
US20090227012A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
CO5560582A2 (es) Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ECSP064643A (es) Proteinas de fusion de glp-1
BRPI0511008A (pt) agentes de ligação de il-13
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
ATE428785T1 (de) Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
AR073856A2 (es) Polinucleotido que codifica un polipeptido con actividad de alfa-amilasa y casete de expresion que lo comprende.
CR7584A (es) Nuevas proteinas de fusion con trombomodulina dirigidas contra factores tisulares como anticoagulantes
NZ568769A (en) Human monoclonal antibodies against CD20
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
HRP20090245T1 (en) Pyy agonists and uses thereof
PE20090711A1 (es) Region constante de anticuerpo mutante
GT200000200A (es) Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.
DE60334700D1 (de) Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren
CO6160304A2 (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores
ES2111066T3 (es) Unidad minima de reconocimiento de un anticuerpo monoclonal especifico con repeticion del tandem mucina pem.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
PE20080187A1 (es) Agonistas receptores de eritropoietina
ES2152216T3 (es) Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.
NZ596984A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
DE69231918D1 (de) Peptidantagonisten des bradykinin
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
HUP9901411A2 (hu) Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása

Legal Events

Date Code Title Description
FG Application granted